Astria Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update

-- Administration of STAR-0215 to HAE Patients is Underway in the ALPHA-STAR Phase 1b/2 Trial ---- ALPHA-STAR on Track for Initial Proof-of-Concept Results Anticipated Mid-2024 ---- Mechanistic Modeling Data Supports STAR-0215 Administration Once Every Three or Six Months for Robust Suppression of HAE Attacks --BOST...

Related Keywords

United States ,American ,Marcus Maurer ,Andrea Matthews ,Jillc Milne ,Instagram Astriatx ,Astria Therapeutics Inc ,Corporate Communications ,Nasdaq ,Linkedin ,American Academy Of Allergy ,Office At Astria ,Facebook ,Neither The Company ,Drug Administration ,Twitter ,Business Development ,Exchange Commission ,Initial Proof Of Concept Results Anticipated ,Once Every Three ,Six Months ,Robust Suppression ,Astria Therapeutics ,Chief Executive Office ,Inhibitor Deficiency ,Angioedema Workshop ,Principal Investigator ,American Academy ,Immunology Annual Meeting ,Chief Business ,Corporate Strategy ,Investor Relations ,Patient Advocacy ,Loss Per Share Basic ,Annual Report ,Months Ended March ,Consolidated Statements ,Cash Flows ,